Donny Hanjaya-Putra

Hanjaya Putra Donny 1

Assistant Professor, Department of Aerospace and Mechanical Engineering, and Assistant Professor (Concurrent), Chemical and Biomolecular Engineering, College of Engineering

Phone: 574-631-2291

Office: 141 Multidisciplinary Research Building



Lab Website

Our laboratory works at the interface of engineering and medicine, with a motivation on making stem cell and molecular therapies as an effective method to model and treat diseases. Toward these goals, we integrate our core expertise in stem cell engineering, biomaterials synthesis, and micro/nano- technologies for their application in regenerative medicine, disease modeling, and drug delivery.

  1. Stem Cell Engineering. Stem cells have the potential to induce repair and participate in regenerating injured tissues. However, during the course of chronic diseases (e.g., cardiovascular diseases and diabetes) and aging, resident and circulating stem cells are subject to stress-induced premature dysfunction that limits their therapeutic use. Our lab is interested to utilize engineering approaches to understand the mechanisms governing stem cell fate and to control stem cell differentiation, in particular for their therapeutic application in cardiovascular and lymphatic disorders.
  2. Biomaterials for Stem Cell Morphogenesis. Promoting blood and lymphatic vasculature is important for tissue engineering and can be used as therapeutic interventions to treat ischemia and lymphedema. We are studying the role of growth factors and extracellular matrices (ECMs) in blood and lymphatic formation. Our lab utilizes bio-mimetic materials with spatial and temporal control for stem cells to undergo morphogenesis into vascular and lymphatic vasculatures. We are applying this approach toward therapeutic interventions to treat ischemia, lymphedema, and wound healing in animal models.
  3. Targeted Drug Delivery. Many available drugs are effective at a very small therapeutic window without causing systemic side effects. For example, anti-coagulant drugs are effective at preventing blood clots, but can also cause systemic bleeding. To overcome these limitations, we are interested in harnessing the ability of stem cell and antibody for site-specific delivery of therapeutics.

Would you like to support Prof. Hanjaya-Putra's research?